Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $32.83.
Several analysts have issued reports on the company. Mizuho set a $27.00 target price on Corvus Pharmaceuticals in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Monday. Finally, LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th.
View Our Latest Report on CRVS
Corvus Pharmaceuticals Price Performance
CRVS opened at $10.23 on Friday. The business’s fifty day moving average is $12.03 and its 200-day moving average is $14.34. Corvus Pharmaceuticals has a 52-week low of $6.39 and a 52-week high of $26.95.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, research analysts expect that Corvus Pharmaceuticals will post -0.79 earnings per share for the current year.
Hedge Funds Weigh In On Corvus Pharmaceuticals
Several large investors have recently modified their holdings of the stock. Ancora Advisors LLC boosted its holdings in shares of Corvus Pharmaceuticals by 3.6% during the 2nd quarter. Ancora Advisors LLC now owns 56,723 shares of the company’s stock valued at $847,000 after acquiring an additional 1,955 shares during the last quarter. Global Retirement Partners LLC bought a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $30,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $48,000. Avity Investment Management Inc. boosted its holdings in Corvus Pharmaceuticals by 11.9% in the second quarter. Avity Investment Management Inc. now owns 37,150 shares of the company’s stock worth $555,000 after purchasing an additional 3,950 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Corvus Pharmaceuticals in the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company’s research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.
Corvus’ leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma.
Read More
- Five stocks we like better than Corvus Pharmaceuticals
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
